BSX · Earnings call · 2026Q3T · Full report

Revenue Performance and Mix

BOSTON SCIENTIFIC CORP · 2026-10-28 · Importance 31 · Surprise 32 · No source text

Q3 2026 consolidated revenue was $5.14 billion, up 1.5% year over year, below the 3%–5% guidance range. Organic revenue growth was also 1.5%, and management estimated the cyber incident reduced growth by approximately 300 basis points. Interventional Cardiology and Vascular Therapies grew 12%, including 19% growth in interventional cardiology, while Neuromodulation grew 13%. WATCHMAN sales declined 7% in the U.S. and grew 4% internationally; EP sales declined 5%, with an 8% U.S. decline and 2% international growth.

Key facts

• Q3 2026 consolidated revenue was $5.14 billion, up 1.5% reported year over year; foreign exchange was neutral.
• Boston Scientific's business historically representing approximately 75% of the company grew approximately 6% to 7% for many quarters.
• Q3 2026 organic sales grew 1.5%, below the original guidance range of 3% to 5%.

Impact estimates